Tenofovir Df + Emtricitabine + Rilpivirine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg
Reference Brands: Complera(US); Eviplera(EU)
Category:
Anti Viral
Tenofovir DF + Emtricitabine + Rilpivirine, sold as Complera (US) and Eviplera (EU), is a once-daily HIV-1 treatment combining three antiretrovirals in one tablet. It’s FDA and EMA approved and must be taken with food.
Tenofovir DF + Emtricitabine + Rilpivirine is available in Tablet
and strengths such as TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tenofovir DF + Emtricitabine + Rilpivirine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tenofovir DF + Emtricitabine + Rilpivirine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Rilpivirine is a once-daily, fixed-dose combination used for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. Marketed under the brand names Complera (US) and Eviplera (EU), it combines three powerful antiretroviral agents: TDF (a nucleotide reverse transcriptase inhibitor), Emtricitabine (an NRTI), and Rilpivirine (a non-nucleoside reverse transcriptase inhibitor). This single-tablet regimen simplifies HIV treatment, enhances patient adherence, and effectively suppresses viral load. Approved by the FDA and EMA, it is recommended for patients without resistance to any of its components and should be taken with a meal for optimal absorption.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing